
The impact of our research programme
Celebrate how the achievements of our research programme last year (July 2022 – June 2023) are taking us one step closer to improving access to treatments for all.
Read our latest updates from research breakthroughs to government actions to fundraising heroes.
Celebrate how the achievements of our research programme last year (July 2022 – June 2023) are taking us one step closer to improving access to treatments for all.
Dr Sharon Tate, Head of Primary Care at Target Ovarian Cancer, talks to Overlooked podcast host Golda Arther about the importance of GP engagement and how that, along with symptoms awareness, is a needle mover when it comes to progress in ovarian cancer.
The European Society of Medical Oncology congress (ESMO) is held annually to present new clinical data and research findings alongside educational updates and programmes aimed to improve cancer care.
Driving awareness and improvements in ovarian cancer is happening, but your help is vital
Ahead of our upcoming wellbeing event, we’ve put together five tips from our previous events, shared by trusted experts and specialists, to help you explore a range of practical advice, sessions and support.
After first being diagnosed with stage 4b ovarian cancer in January 2021, Sue took part in the Ovarian Cancer Walk|Run in 2022. This year, she's joining us again!
The support and expertise of Clinical Nurse Specialists (CNSs) is at the heart of ovarian cancer care. Celebrate them with us through our new award.
Gynae Cancer Awareness Month is from 1-30 September and is a chance to shine a spotlight on ovarian cancer as one of the five gynaecological cancers.
Hear first-hand from husband and wife, Declan and Pauline, about how our supportive services helped them individually and together.
Learn about our newly launched tools and resources that put support and trusted information in the spotlight. Introducing our new stages tool, PARP inhibitor eligibility tool and Your Wellbeing hub.
From diagnosis and wait times, to accessing the best treatments available, we recognise that there is still a significant variation in experience across the UK. We want to change this.
Led by Professor James Brenton, this project explored the immune system and its potential to transform ovarian cancer treatments by learning more about high-grade serous ovarian cancer (HGSOC) tumours.
Sign up to receive emails and keep up to date on all things Target Ovarian Cancer
Sign up